The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

On September 10, experts across disciplines, from infectious disease clinicians to regulators to representatives from the pharmaceutical industry, convened at the inaugural ImmunOptimize workshop in ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Common HIV Treatments May Aid Alzheimer's Disease Patients Apr. 16, 2024 — Scientists have identified promising real-world links between common HIV drugs and a reduced incidence of Alzheimer's ...

The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...

People living with HIV who need a kidney can rest assured that outcomes are similar whether their kidney donor was ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...

Alchemy, which sets up pharmacies in community clinics, said that it had raised $31 million from Andreessen Horowitz and ...

The data from 31 presentations across HIV treatment and prevention ... in combination with an optimized background regimen in people with multi-drug resistant HIV. HIV prevention data will ...

Here is a list of anti-seizure medication (ASM), previously called anti-epileptic drugs or AEDs, with links to information about what type of seizures they are used for, doses, and possible side ...